US pharmacies claim govt report proves closure cause

21 January 2008

The US Department of Health and Human Services' Office of the Inspector General has released figures which, a pharmacy group argues, demonstrate that "inadequate" reimbursements under the Medicare Part D prescription drug benefit for seniors (Marketletters passim) are responsible for outlet closures. According to a report by the Associated Press, pharmacists receive $2 less per prescription under the new program than they do for Medicaid dispensed drugs. However, the OIG study did not specifically take a view on whether the arrangements under the Medicare program were adequate.

Mike James, the government affairs director of the Association of Community Pharmacists, said that most local pharmacies would need to raise charges by up to 21% to remain economically viable, instead of the 18% currently levied. Of the more than 1,000 pharmacies to close down in 2007, Mr James claimed that many had cited the reimbursement discrepancy as a factor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight